2013-2014年季节性流行性感冒疫苗免疫血清针对我国流行株的抗体水平分析

目的 分析季节性流行性感冒(流感)疫苗免疫血清针对我国流行株的抗体水平及我国流行株与疫苗株的匹配性. 方法 采集不同年龄组人群疫苗接种前后的血清,利用流感流行株和疫苗株作为病毒抗原,应用血凝抑制试验(HI)方法对血清进行检测. 结果 三价流感疫苗对我国A(H1N1)Pdm09亚型流行株产生的抗体平均几何滴度(GMT)低于针对疫苗株病毒的GMT,血清抗体滴度 40的比例为57.0%～63.3%;对我国A(H3N2)亚型流行株产生的GMT与针对疫苗株病毒的GMT类似,血清抗体滴度超过40的比例为57.6%～63.0%;对B型流行株产生的血清抗体GMT低于针对疫苗株的GMT,不过超过了疫苗株抗体GMT的50%.不同年龄组的血清抗体反应不同,成年组相对较高. 结论 2013-2014年季节性流感疫苗与同期流行的A(H1N1)Pdm09亚型流感病毒和B型流行株Yamagata系流感病毒较为匹配;H3N2亚型疫苗与流行株的匹配性较低,有可能会导致疫苗的保护效果降低.

Post immunization sero-antibody level to circulating influenza viruses induced by seasonal influenza vaccine in China

Objective To understand the post immunization sero antibody level to circulating influenza viruses induced by seasonal influenza vaccine and the matching of vaccine strains with circulating strains. Methods Pre and post immunization serum samples were collected from people in different age groups. Hemagglutination inhibition(HI) assay with circulating strain and vaccine strain as antigen was conducted to detect the serum antibody level. Results The antibody geometrical mean titer(GMT) of trivalent influenza vaccine to influenza A(H1N1) pdm09 strain in China was lower than that to vaccine strain, the proportion of serum samples with antibody titer 40 was ranged from 57.0% to 63.3%. The GMT of antibody induced by influenza vaccine to circulating H3N2 influenza strains was similar to that to vaccine strain, the proportion of serum samples with antibody titer 40 ranged from 57.6% to 63.0%. The GMT of antibody induced by influenza vaccine to circulating influenza B strain was lower than that to vaccine strain, but was more than 50% of the GMT antibody of the vaccine virus. The adult group had relatively higher serum antibody level than the other age groups. Conclusion The composition of seasonal influenza vaccine of 2013-2014 matched with the circulating influenza A(H1N1) pdm09 and influenza B strains Yamagata lineage; the mismatching of influenza A(H3N2) vaccine strain with the circulating influenza A(H3N2) strain would reduce the effectiveness of the vaccine.